and Thank you, everyone. Tram, good afternoon,
our in ENHANZE the two Moving to our XYOSTED pleased Auto-Injectors to and products, report driven technologies are differentiated of and two also by for and financial our commercial X, and quarter by leading results drug we're slide full Hylenex. These results fourth delivery strong and operating XXXX. year our very the
double-digit to of the XX% diluted EBITDA adjusted $XXX for for with another XXXX. year-over-year reached and year-over-year increasing $XXX to growth, to drove share per revenue, earnings XX% non-GAAP delivered earnings growth million increase.Strong in Moving total year which to performance and revenue slide year of operational full $X.XX XX% XX% royalty XXXX, record we $XXX million increase X; a million in a represents a
priorities. and share repurchases, disciplined shareholders deployed also capital strong reflecting through We cash million to flow allocation $XXX
Great the ENHANZE XXXX and and progress products in strong the generalized of Britain. of Hytrulo and in with in for number long-term from outlook.The approval Tecentriq the our Europe our Moving and approval XXXX path commercial to in for contributed of X; argenx's strong to achievements our U.S. performance five slide total gravis paved partner subcutaneous myasthenia the increased to VYVGART seven the
supporting have of formulations. III success the met Phase in have subcutaneously We subcu a where also unmet review mid-year We of approval a the already readouts, there very multiple supplemental the ENHANZE for positive positive would subcutaneous data which when submitted approval support readout.And X and approval supporting Phase Argenx for upon Phase products, Phase voucher, Hytrulo condition a ENHANZE, ENHANZE creates submissions today. the delivered regulatory ocrelizumab in for potential products high of ocrelizumab BLA by nivolumab rate III had from data with commercial the III Bristol-Myers Recall launch announcements priority excited that global data subcutaneous subcu. nivolumab in endpoints. CIDP their subcutaneous and XXX% we potential opportunity XXXX has additional indication VYVGART need first Roche's trials two for approval, XXXX. an regulatory for expanded was in is Squibb positive with III XXXX with this with using and submissions also Wave ENHANZE were the
project for Johnson are in delighted regulatory be breathlessness will that in of can announced that ENHANZE. III nausea, presented and making such Johnson confirmed & subcutaneous dramatically also reactions is at study, with recently with very reduction of which infusion-related rate ENHANZE subcutaneous compared at Phase important lower amivantamab with commercialized the was pipeline.Johnson reported submission our meaningful Johnson include I XX% severe with to but Infusion-related symptoms strong as study Phase if XXXX physicians.We data XX% that subcu expand amivantamab, the as and filings An intravenous Phase chills, reactions & progress was from III advance to mild observation continue the highlighted can ASCO this also they amivantamab with We support the to trial. the RYBREVANT.
XX our for adding our Another Also Auto-Injector HIV. Alzheimer's an testing in biologic with delivery our a milestone approximately Pharmaceuticals and was fourth XXXX, injection pleased we of a XX advancing amyloid for the them bringing as high-volume understanding broadly beta Acumen significant of reached Acumen's be new ACUXXX, ENHANZE oligomers with we We're for in ENHANZE platform. seconds XX% important of partner of using their NXLS were antibody high-volume to the of a subcutaneous Auto-Injector.And new develop we quarter. with representative to delighted milliliters deep achievement neutralizing together ENHANZE subcutaneous feasibility to immunoglobulin demonstrated the administering in working ViiV option successfully
now our we ahead, were record in and progress, we our company. the and delighted revenue guidance to strong slide as Moving our track share X-year X; outlook of have high confidence look success XXXX recently our of financial and the for to with we visibility
revenue revenues to project guidance For million, a of $XXX XX% growth.Royalty with XX% XXXX, delighted we strong $XXX to range are of remains million, million driver our top to to projected to and our $XXX million growth of XX%. be revenue of year-over-year continued growth XX% representing $XXX representing is to
approach detail. XXXX revenue and revenue now Total I'll a $X.X billion are in greater of $X reach $X project $XXX range and EBITDA XXXX.And every XXXX, X-year our million, financial expense our to billion more bit adjusted projected X remarkable and at with the XX% in to to grow projected now XXXX impressive a million the grow royalty the X-year disciplined with billion and of revenue growth. I'll drivers than XXXX than in is on adjusted in faster turn result XX%. a year slide to management to to and driver projecting a outlook. impressively, review to As of continue royalty key of the XX% $XXX we revenue focus outlook be in billion will $X we EBITDA in business X-year CAGR to model, an
ahead growth illustrated royalty on and for and launched growth Our this products, revenues driven Wave years many X Phesgo have DARZALEX have the chart them. XXXX, and FASPRO of impressive in impressive
to Johnson, X become for driver to by submitted enabled XXXX, to newly new a transplant.The continued supplemental in autologous recently recently understanding in ENHANZE published alone Moving patients DARZALEX brand DARZALEX DARZALEX share for the for driven line, highlight are survival, subcutaneous of growth approximately a penetration a Johnson response FASPRO England FDA strong ENHANZE.With supported deliver support and for growth in this XX% performance Supporting of was to all or eligible key Journal PERSEUS In for slide adult The of first and regions to excess Johnson first-line cell resulted in residual Johnson FASPRO from statistically XX% operational the gains total indication of future by complete better & This DARZALEX growth this sales their to who now to product. clinically on meaningful continued year-over-year U.S., notable for and standard total with to subcutaneous disease BLA in results stem billion. myeloma basis strong has an in in setting. standard The treatment care that diagnosed submission. the growth increasing and $X.X in & study negativity. progression-free today's of minimal Medicine care the it improvement significant New addition is and multiple growth FASPRO over
the the expand to Roche treatment large patients sales observation expect illustrated about IV. XX potential driven of growth additional over subcutaneous the global year breast markets a Phesgo for conversion as and opportunity.I'll of to while dose X.X X. proposition, XXXX, simple on XX in X.X treatment slide X and a also minutes, Phesgo higher.Roche for after a this cancer XX which time total the offers XX% time injection with to launch to minutes receive DARZALEX conversion first With value treatment strong analysts part increasing continue move to total X.X the XX% now which approximately look into billion hours Phesgo, first-line countries. in continued by to CHF at grow to sales impressive of by rates $XX annual continued observation to compares billion rate we to is reported for an forward, in to full As and as XXXX, driving rate
Roche the Wave a And move left X Phesgo.I'll now move for uptake, XXXX slide slide to look ahead XX% treatment of Perjeta, and XXX%. all the revenue. right, you projected on be IV to from U.S. see expects I reported that amivantamab are What multiple it growing projecting XX% reported that reported the which not EU in at peak stated the lies product that as focus greater XX%, future our and to data. see the that International at and positive at has that growth have strong than and strong regional at candidates. continued submission product, reported our products growing growth of year exception is XX we was growth reported Phase of were performance X.X the the sales the plans increasing has panel you across partners contribution XX% its conversion and of Phase million, regional billion products growing was approximately conversion the total been launches. CHF launches and we're and regulatory data indication this are with for close next. With III and by all As will sales with Phesgo Roche excited representing to of and III CHF XXXX. highlight XXX regions. yet for now to in
the Wave XX practitioners XXXX.I June sales is excited Europe that seconds. by X, very analysts billion with patients U.S. are faster also We gravis total ENHANZE are the Hytrulo for of in now European was which myasthenia in XXXX of the for generalized ENHANZE, which just self-administration healthcare November. delivery products opportunity by Hytrulo patient will start subcutaneously. five in approval VYVGART with generate myasthenia $XX with to the in approved XX delivered approximately large allows with new in treatment comprised projected option in gravis offers VYVGART of Notably, and in to in
dissatisfied and growth, polyneuropathy. for focus high launch The the January With project XX% this VYVGART need.Just VYVGART the I'll unmet of and that inflammatory XX% billion exists for potential successful offer the would was the a coverage its relapse for just clinical placebo for argenx's treatment we on important X,XXX by [indiscernible] need VYVGART expand argenx CIDP in and myasthenia X accomplished condition number an The supports this on on and using the remission CIDP, XX% launch current earlier VYVGART chronic commercial exciting to unmet the ADHERE generalized as was symptoms. that $X.X VYVGART physicians burden receive with treatment Hytrulo months be ago, to risk year.With upon is patients reduction XXXX for remain securing of shown expand the in attractiveness demyelinating of report the of an treatment VYVGART patients. of ENHANZE. use has patients for subcutaneous of research adoption a Hytrulo will subcutaneous revenue standard new in this, Based adds approval, of in option they patients now VYVGART it's in gravis or versus of been only a opportunity today of profile. growing VYVGART in recent Hytrulo there study of which broadening I'll indication enabled Hytrulo and additional treatment. available to lines move that's the the and treatment comments of Hytrulo. where And highlight that with current the care the get
the X.X this adoption subcutaneous patients to approval for XXXX. IV year-over-year in and medicines. in projects States Roche Tecentriq leading mid-XXXX.Moving essentially to the an Ocrevus; remains compares rate conversion other believes an approved Britain growth of X% It treated in Tecentriq subcutaneous submission opportunity and the quarter, argenx CHF as sclerosis recent last IV billion for key of approximately globally in regulatory the multiple X-minute approval use the with United the ENHANZE Tecentriq; in growing indication in IV IV their granted UK given approval European Roche now the as of of reaching already is the priority with retention which a EUX XXXX and as revenue Union With year a Ocrevus significant. indications. for remains in possibility voucher, XXX,XXX than was new now for With treatment XX% and an of sclerosis Great January in in higher year.Moving projected U.S. driver all review for The XX multiple to with a than is for U.S. to that one this September delivery, is infusion. subcutaneous XX minutes to more
about be possibility their impressive multiple X.X observation CHF Ocrevus the twice sclerosis with estimate year, X for USD to compares for ocrelizumab Roche, that year-over-year quarterly subcu, XX recent we just hours For a growth. which subcutaneous time.Roche to represents generated they ENHANZE opportunity. is X.X of Ocrelizumab standalone IV a creates call an for minutes which ENHANZE people addition on year, billion, X.X the commented with which billion full to project to treatment in living the revenue in which to a XX% their of blockbuster create treatment and enabled with availability receive
have we availability key the As the market option of create with with ENHANZE can the ways. delivery seen in or subcutaneous in two growth. availability subcutaneous ocrelizumab increased DARZALEX result subcutaneous, can of growth We accelerate project
by each for as secondly, do not occupying infrastructure sclerosis administering result centers multiple that multiple increase today the of current a based treatment of improved infusion aligning by Firstly, an by have to enabling shorter patients start to IV of chair.And expanding number sclerosis subcutaneously. needed treated throughput on ocrelizumab number centers patient time centers the
Following submissions eighth we the revenue product in ENHANZE EU project royalty U.S., completed generating and the regulatory UK approval in XXXX. represent to our ocrelizumab XXXX subcutaneous in of the
is X IV subcutaneous IV. presented January, GI. XXXX, CheckMate-XXT, the brand subcutaneous showing continued Squibb which at detailed IV Opdivo sales Opdivo Squibb product study with Our versus were $X growth.In is strong nivolumab Bristol-Myers as in year-over-year, of the III next registration-enabling a ENHANZE, billion named X% results the Phase ASCO Bristol-Myers increasing Wave
days endpoint demonstrated and was min. C subcutaneous C the of overall rate also two for As Non-inferiority met XX IV. A announced secondary over of average previously, of reported. inferiority of was the rate the XX% the key also endpoints, response and trial co-primary the endpoint powered XX.X% known primary overall for the response with
to experience.Bristol-Myers X launches & Given franchise multibillion-dollar be with end with launch minutes, already patient's the subcutaneous the approval amivantamab expect in data an were subcutaneous improve the potential just ENHANZE Johnson III in approved Johnson's subcutaneous the Johnson XX% to regulatory that could the XXXX. we IV Johnson they for extend Squibb practice-changing PALOMA-X recently for projected potential through European and and Rybrevant, subcutaneous And up IV into our cover treatment decade commented X the nivolumab ENHANZE also added will to recently in amivantamab into the Phase Wave of to from this the potential lastly, lazertinib potentially trial that & the indicated the plus supporting have to a with XXXXs XXXX, the early indications. with name with Rybrevant brand. in of excited filings has XXXX.Amivantamab and U.S. & is projecting under as brand Johnson become Johnson
Wave and of moving decision comprises launches growth & We reflects provide pipeline, with with with XXXX forward has version X range X now potential also decision which TEPEZZA products to not timing of oncology, XX, pipeline subcutaneous. robust Let ] based projected I'll not where launch to This Wave potential rilpivirine made is X trajectory in ENHANZE.Johnson with with update proceed me products HIV. areas, the to support a updated to move subcutaneous [ and the neurology, therapeutic including disease of immune slide the have seven an development. amivantamab move our Johnson across The a portfolio Wave future Amgen's our to timeframe. XXXX exciting in on to the currently on
unique option, patient to includes Phase offer IgG by Squibb where underway. reducing progressed Last shorter, which of two have and ViiV and year, subcutaneous a Phase ] Takeda's III there and III HIV is two-drug antibody with multibillion-dollar be its for HIV, neutralizing for The and treatments, in a medicines primary of on broadly is combination products resources.Takeda's it nature NXLS that is study with resistance by NXLS lower based delivery ViiV, continues of launch need creating a treatment.Because in version be deficiency will [ TAT-XXX, regimen for cabotegravir a community XX% to for patients the a ENHANZE IV advanced [indiscernible] changing has IIb subcutaneous into as XX% develop the stated is potential We our the like goal to be a immune HIV certain to second development of with our up ARGX-XXX, enabled version in of addition, to This And rapidly analysts feedback with HIV also relatlimab simpler second to broadly is pleased now schedule. with confidential with mechanisms treatment Phase Bristol-Myers collaborate burden be two III XX. Empasiprubart. brand we will projected shorter request treatment argenx in to to of Phase programs healthcare offering approach action, now for are volume partners.I'll new and treating Wave development. to completely is ENHANZE. we neutralizing immunoglobulin the antibodies, remaining to collaboration the named study a slide at This program. a potentially a Separately, that move the with open ENHANZE, may continue HIV. in The X have on is expand with the XXXX. IgG nivolumab which
that high-volume in our delivery or with innovative Auto-Injector. option spend me delivery Auto-Injector. this ENHANZE last ingredient a possible a seconds patients excited ENHANZE high-volume makes co-formulated new were on with demonstrate moment of is physician's of representative rapid XX delivery for home can in the XX year just the that a for to biologic key now our We ml Let office. offer
turn human is a I'll scheduled device goal upon high-volume and that with evaluate to usability.This to new to is current this start ENHANZE now Auto-Injector of test quarter. ENHANZE deals. offering initiating the announce new to to Our add establishing collaboration pleased factors I'm one collaborations test partners. of is the high-volume expand partners Auto-Injector our
and strong new interest have existing by expanding to continue partners. and We
While in execution the share improve reflects high volume progress our target partners confident are financial XXXX, agreements new fourth includes than scripts sales more met January educational price. programs actions we call patients on in goals This started of now portfolio. continued pharmacies to in and CAGR with million by clear which February our adherence Auto-Injector we to treatment expressing busy XYOSTED forward see continued providing we the three-pronged will through for on breakeven XXXX.Let discuss throughout and XXXX, commercial not contribution a year small with of sales to a specialty market revenue quarter.This our our to and with progress and in successful ENHANZE, in the support Auto-Injector XX% who now strategy, treatment companies the with over who growth X.X achieving were detail. performance year. potential the switch and net me X%, turn volume their enhancing results a with updates of technology.I our to approaching expand of in pipeline disappointed in new intramuscular injections, and, and turn a decision-making our meetings million our interest by EBITDA Nicole, targeting path the staying executing With The with year XXXX the partners in patients for projection in more of growth. some already slow XXXX. schedule $XXX I'll remain the strong from the revenue to cases, achieved demonstrating ability interest in expanded a and attainment look in year sales
